These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 29848670)

  • 21. Gastric cancer and the epoch of immunotherapy approaches.
    Niccolai E; Taddei A; Prisco D; Amedei A
    World J Gastroenterol; 2015 May; 21(19):5778-93. PubMed ID: 26019442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined-modality therapy for gastric cancer.
    Yao JC; Mansfield PF; Pisters PW; Feig BW; Janjan NA; Crane C; Ajani JA
    Semin Surg Oncol; 2003; 21(4):223-7. PubMed ID: 14648779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer of the esophagus and gastric cardia: recent advances.
    Tytgat GN; Bartelink H; Bernards R; Giaccone G; van Lanschot JJ; Offerhaus GJ; Peters GJ
    Dis Esophagus; 2004; 17(1):10-26. PubMed ID: 15209736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent advances in multimodal treatment for gastric cancer: a review.
    Lordick F; Siewert JR
    Gastric Cancer; 2005; 8(2):78-85. PubMed ID: 15864714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perioperative therapy for resectable gastric cancer: what does the future hold?
    Chong G; Tebbutt NC
    Asia Pac J Clin Oncol; 2011 Jun; 7(2):93-5. PubMed ID: 21585687
    [No Abstract]   [Full Text] [Related]  

  • 26. Esophagogastric junction and gastric adenocarcinoma: neoadjuvant and adjuvant therapy, and future directions.
    Sandler S
    Oncology (Williston Park); 2014 Jun; 28(6):505-12. PubMed ID: 25134325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Neoadjuvant therapy for tumors of the upper gastrointestinal tract : Complication management].
    Gockel I; Hoffmeister A; Lordick F
    Chirurg; 2015 Nov; 86(11):1014-22. PubMed ID: 26374651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant and neoadjuvant approaches in gastric cancer.
    Ng K; Meyerhardt JA; Fuchs CS
    Cancer J; 2007; 13(3):168-74. PubMed ID: 17620766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.
    Van Cutsem E; Van de Velde C; Roth A; Lordick F; Köhne CH; Cascinu S; Aapro M;
    Eur J Cancer; 2008 Jan; 44(2):182-94. PubMed ID: 18093827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of oesophageal carcinoma.
    Mackay S; Stefanou G
    Aust Fam Physician; 2006 Apr; 35(4):202-6. PubMed ID: 16642235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
    Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does chemoradiotherapy improve outcomes for surgically resected adenocarcinoma of the stomach or esophagus?
    Solomon NL; Cheung MC; Byrne MM; Zhuge Y; Franceschi D; Livingstone AS; Koniaris LG
    Ann Surg Oncol; 2010 Jan; 17(1):98-108. PubMed ID: 19777191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer.
    Park R; Williamson S; Kasi A; Saeed A
    Anticancer Res; 2018 Oct; 38(10):5569-5580. PubMed ID: 30275174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oligometastatic Gastroesophageal Adenocarcinoma: Molecular Pathophysiology and Current Therapeutic Approach.
    Jung JO; Nienhüser H; Schleussner N; Schmidt T
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Gastric cancer--risk factors and medical therapy].
    Harder J; Opitz OG
    Praxis (Bern 1994); 2006 Jun; 95(25-26):1021-8. PubMed ID: 16836062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome.
    Ajani JA; Mansfield PF; Crane CH; Wu TT; Lunagomez S; Lynch PM; Janjan N; Feig B; Faust J; Yao JC; Nivers R; Morris J; Pisters PW
    J Clin Oncol; 2005 Feb; 23(6):1237-44. PubMed ID: 15718321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stage-specific therapy for cancer of the oesophagus: a new 'cancer of the elderly'.
    Krasna MJ
    Drugs Aging; 2009; 26(3):185-94. PubMed ID: 19358615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Esophageal cancer: adjuvant therapy.
    Ku GY; Ilson DH
    Cancer J; 2007; 13(3):162-7. PubMed ID: 17620765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of neoadjuvant versus a surgery first approach for gastric and esophagogastric cancer.
    Russell MC
    J Surg Oncol; 2016 Sep; 114(3):296-303. PubMed ID: 27511285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis.
    Li Z; Shan F; Wang Y; Zhang Y; Zhang L; Li S; Jia Y; Xue K; Miao R; Li Z; Ji J
    PLoS One; 2018; 13(1):e0189294. PubMed ID: 29370182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.